-
Deciphering metastatic route-specific signals and their microenvironment interactions in peritoneal metastasis of gastric cancer Cancer Commun. (IF 16.2) Pub Date : 2024-03-18 Ki Tae Kim, Jae Eun Lee, Jae-Ho Cheong, In Cho, Yoon Young Choi
Gastric cancer (GC) is a pervasive global malignancy with high mortality rates due to distant metastasis [1]. GC metastasis can occur via hematogenous route, peritoneal route, and specifically through ovarian spread in females [2]. Among these, peritoneal metastasis is the most prevalent and challenging condition to treat [3]. The Cancer Genome Atlas (TCGA) has uncovered four molecular subtypes of
-
Disclosing the true impact of screening endoscopy in colorectal cancer prevention Cancer Commun. (IF 16.2) Pub Date : 2024-03-18 Thomas Heisser, Carlo Senore, Michael Hoffmeister, Lina Jansen, Hermann Brenner
Preprint: https://doi.org/10.1101/2022.11.22.22282622 Randomized trials, cohort and modeling studies have consistently demonstrated a major impact of screening endoscopies on reducing colorectal cancer (CRC) incidence and mortality [1]. Over time, CRC mortality starts to be lower in those who underwent screening compared to those who did not due to earlier detection of prevalent, preclinical (asymptomatic)
-
Impact of pre-existing cardiometabolic diseases on metastatic cancer stage at diagnosis: a prospective multinational cohort study Cancer Commun. (IF 16.2) Pub Date : 2024-03-15 Anna Jansana, Aviane Auguste, Marina Kvaskoff, Agnès Fournier, Emma Fontvieille, Laia Peruchet-Noray, Carine Biessy, Reynalda Cordova, Kristina Elin Nielsen Petersen, Anne Tjønneland, Verena Katzke, Rudolf Kaaks, Fulvio Ricceri, Salvatore Panico, Paolo Contiero, Maria-Jose Sánchez, Jesus Castilla, Marta Crous-Bou, Alicia Heath, Elom Kouassivi Aglago, Elisabete Weiderpass, Marc James Gunter, Pietro
Owing to shared risk factors between cardiometabolic diseases (CMDs) and cancer, coupled with population aging, the lifetime risk of an individual developing cancer after a CMD is increasing. Furthermore, biological mechanisms such as insulin resistance or inflammation may not only predispose individuals with CMD to an elevated risk of certain types of cancer but also to a diagnosis of cancer at an
-
The mechanism of resistance to CDK4/6 inhibition and novel combination therapy with RNR inhibition for chemo-resistant bladder cancer Cancer Commun. (IF 16.2) Pub Date : 2024-03-11 Zhichao Tong, Yubo Zhao, Shiyu Bai, Benedikt Ebner, Lou Lienhard, Yuling Zhao, Ziqi Wang, Qi Pan, Pengyu Guo, Thilo Bracht, Barbara Sitek, Jürgen E. Gschwend, Wanhai Xu, Roman Nawroth
Bladder cancer (BCa) is the most prevalent urological cancer worldwide [1]. A significant proportion of BCa (89%) exhibits molecular alterations in the cell cycle pathway, and targeting cyclin-dependent kinases 4 and 6 (CDK4/6) is deemed as a promising therapeutic strategy [2]. Selective inhibitors of CDK4/6 (CDK4/6is) have been approved by the US Food and Drug Administration (FDA) [3]. They could
-
Revealing the secret behind Epstein-Barr virus-specific tumor immune contexture Cancer Commun. (IF 16.2) Pub Date : 2024-03-06 Chu-Xia Deng
Immune checkpoint inhibitor (ICI) therapy has significantly revolutionized cancer treatment across various malignancies, offering distinct and enduring clinical advantages [1]. Gastric cancer (GC) represents a widespread and life-threatening malignancy with substantial global health implications [2]. However, ICI therapy has not produced satisfactory therapeutic responses in GC patients. Presently
-
Unveiling quality of clinical trial in China: from concern to confirmation Cancer Commun. (IF 16.2) Pub Date : 2024-03-06 Huiyao Huang, Yiru Hou, Hong Fang, Ling Xu, Yue Yu, Huifang Zhang, Jing Zhang, Yu Tang, Gongtao Lan, Wenbao Zhang, Ning Li
The cornerstone of scientifically valid and ethically sound clinical trials is in compliance with established global quality requirements. Although China has made significant progress over the past 20 years in terms of the clinical trial quantity [1], quality and participation in multiregional trials [2], there still remain concerns regarding the trial quality, which could be associated with the self-inspection
-
Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory ALK-positive NSCLC from a phase II study Cancer Commun. (IF 16.2) Pub Date : 2024-02-29 Jing Zheng, Tao Wang, Yunpeng Yang, Jie Huang, Jifeng Feng, Wu Zhuang, Jianhua Chen, Jun Zhao, Wei Zhong, Yanqiu Zhao, Yiping Zhang, Yong Song, Yi Hu, Zhuang Yu, Youling Gong, Yuan Chen, Feng Ye, Shucai Zhang, Lejie Cao, Yun Fan, Gang Wu, Yubiao Guo, Chengzhi Zhou, Kewei Ma, Jian Fang, Weineng Feng, Yunpeng Liu, Zhendong Zheng, Gaofeng Li, Huijie Wang, Shundong Cang, Ning Wu, Wei Song, Xiaoqing Liu
The initial phase II stuty (NCT03215693) demonstrated that ensartinib has shown clinical activity in patients with advanced crizotinib-refractory, anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). Herein, we reported the updated data on overall survival (OS) and molecular profiling from the initial phase II study.
-
SERPINE2 promotes liver cancer metastasis by inhibiting c-Cbl-mediated EGFR ubiquitination and degradation Cancer Commun. (IF 16.2) Pub Date : 2024-02-26 Shiyu Zhang, Xing Jia, Haojiang Dai, Xingxin Zhu, Wenfeng Song, Suchen Bian, Hao Wu, Shinuo Chen, Yangbo Tang, Junran Chen, Cheng Jin, Mengqiao Zhou, Haiyang Xie, Shusen Zheng, Penghong Song
Liver cancer is a malignancy with high morbidity and mortality rates. Serpin family E member 2 (SERPINE2) has been reported to play a key role in the metastasis of many tumors. In this study, we aimed to investigate the potential mechanism of SERPINE2 in liver cancer metastasis.
-
Targeting autophagy overcomes cancer-intrinsic resistance to CAR-T immunotherapy in B-cell malignancies Cancer Commun. (IF 16.2) Pub Date : 2024-02-26 Lu Tang, Huan Zhang, Fen Zhou, Qiuzhe Wei, Mengyi Du, Jianghua Wu, Chenggong Li, Wenjing Luo, Jie Zhou, Xindi Wang, Zhaozhao Chen, Yinqiang Zhang, Zhongpei Huang, Zhuolin Wu, Yuxi Wen, Huiwen Jiang, Danying Liao, Haiming Kou, Wei Xiong, Heng Mei, Yu Hu
Chimeric antigen receptor T (CAR-T) therapy has substantially revolutionized the clinical outcomes of patients with hematologic malignancies, but the cancer-intrinsic mechanisms underlying resistance to CAR-T cells remain yet to be fully understood. This study aims to explore the molecular determinants of cancer cell sensitivity to CAR-T cell-mediated killing and to provide a better understanding of
-
NAT10-mediated ac4C-modified ANKZF1 promotes tumor progression and lymphangiogenesis in clear-cell renal cell carcinoma by attenuating YWHAE-driven cytoplasmic retention of YAP1 Cancer Commun. (IF 16.2) Pub Date : 2024-02-26 Daojia Miao, Jian Shi, Qingyang Lv, Diaoyi Tan, Chuanyi Zhao, Zhiyong Xiong, Xiaoping Zhang
Lymphatic metastasis is one of the most common metastatic routes and indicates a poor prognosis in clear-cell renal cell carcinoma (ccRCC). N-acetyltransferase 10 (NAT10) is known to catalyze N4-acetylcytidine (ac4C) modification of mRNA and participate in many cellular processes. However, its role in the lymphangiogenic process of ccRCC has not been reported. This study aimed to elucidate the role
-
A novel strategy for treating oncogene-mutated tumors by targeting tumor microenvironment and synergistically enhancing anti-PD-1 immunotherapy Cancer Commun. (IF 16.2) Pub Date : 2024-02-09 Yingqiang Liu, Linjiang Tong, Mengge Zhang, Qi Zhang, Qiupei Liu, Fang Feng, Yan Li, Mengzhen Lai, Haotian Tang, Yi Chen, Meiyu Geng, Wenhu Duan, Jian Ding, Hua Xie
Oncogenes are critical factors in tumorigenesis of diverse cancer types and play essential roles in tumor immune escape. Mutations in Kirsten rat sarcoma viral oncogene homolog (KRAS) and epidermal growth factor receptor (EGFR) are among the most frequent gain-of-function alterations [1]. After many years of in-depth research, inhibitors targeting EGFR or KRAS mutations have been successfully developed
-
Cover Image, Volume 44, Issue 1 Cancer Commun. (IF 16.2) Pub Date : 2024-02-06 Monika Raab, Izabela Kostova, Samuel Peña-Llopis, Daniela Fietz, Monika Kressin, Seyed Mohsen Aberoumandi, Evelyn Ullrich, Sven Becker, Mourad Sanhaji, Klaus Strebhardt
-
Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy Cancer Commun. (IF 16.2) Pub Date : 2024-02-04 Bin Song, Ping Yang, Shuyu Zhang
Cancer is a leading cause of death worldwide. Targeted therapies aimed at key oncogenic driver mutations in combination with chemotherapy and radiotherapy as well as immunotherapy have benefited cancer patients considerably. Tumor protein p53 (TP53), a crucial tumor suppressor gene encoding p53, regulates numerous downstream genes and cellular phenotypes in response to various stressors. The affected
-
AP4 induces JNK1 and a miR-22-3p/FOSL1 feed-forward loop to activate AP-1 and promote colorectal cancer metastasis Cancer Commun. (IF 16.2) Pub Date : 2024-01-15 Jinjiang Chou, Markus Kaller, Matjaz Rokavec, Fangteng Liu, Heiko Hermeking
Dear Editor, Colorectal cancer (CRC) is the third most deadly cancer worldwide [1]. The mortality of CRC has remained high due to limited treatment options for metastatic CRC (mCRC) [2]. Epithelial-mesenchymal transition (EMT) is an important contributor to mCRC [2]. The c-MYC proto-oncogene (MYC)-induced transcription factor AP4 (TFAP4/AP4) is a driver of EMT, thereby presumably facilitates mCRC [3
-
Cellular metabolism: A key player in cancer ferroptosis Cancer Commun. (IF 16.2) Pub Date : 2024-01-13 Xianjie Jiang, Qiu Peng, Mingjing Peng, Linda Oyang, Honghan Wang, Qiang Liu, Xuemeng Xu, Nayiyuan Wu, Shiming Tan, Wenjuan Yang, Yaqian Han, Jinguan Lin, Longzheng Xia, Yanyan Tang, Xia Luo, Jie Dai, Yujuan Zhou, Qianjin Liao
Cellular metabolism is the fundamental process by which cells maintain growth and self-renewal. It produces energy, furnishes raw materials, and intermediates for biomolecule synthesis, and modulates enzyme activity to sustain normal cellular functions. Cellular metabolism is the foundation of cellular life processes and plays a regulatory role in various biological functions, including programmed
-
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023 Cancer Commun. (IF 16.2) Pub Date : 2023-12-31 Feng-Hua Wang, Xiao-Tian Zhang, Lei Tang, Qi Wu, Mu-Yan Cai, Yuan-Fang Li, Xiu-Juan Qu, Hong Qiu, Yu-Jing Zhang, Jie-Er Ying, Jun Zhang, Ling-Yu Sun, Rong-Bo Lin, Chang Wang, Hao Liu, Miao-Zhen Qiu, Wen-Long Guan, Sheng-Xiang Rao, Jia-Fu Ji, Yan Xin, Wei-Qi Sheng, Hui-Mian Xu, Zhi-Wei Zhou, Ai-Ping Zhou, Jing Jin, Xiang-Lin Yuan, Feng Bi, Tian-Shu Liu, Han Liang, Yan-Qiao Zhang, Guo-Xin Li, Jun Liang
The 2023 update of the Chinese Society of Clinical Oncology (CSCO) Clinical Guidelines for Gastric Cancer focuses on standardizing cancer diagnosis and treatment in China, reflecting the latest advancements in evidence-based medicine, healthcare resource availability, and precision medicine. These updates address the differences in epidemiological characteristics, clinicopathological features, tumor
-
Development of antibody-drug conjugates in cancer: Overview and prospects Cancer Commun. (IF 16.2) Pub Date : 2023-12-30 Dan-Yun Ruan, Hao-Xiang Wu, Qi Meng, Rui-Hua Xu
In recent years, remarkable breakthroughs have been reported on antibody-drug conjugates (ADCs), with 15 ADCs successfully entering the market over the past decade. This substantial development has positioned ADCs as one of the fastest-growing domains in the realm of anticancer drugs, demonstrating their efficacy in treating a wide array of malignancies. Nonetheless, there is still an unmet clinical
-
NHE7 upregulation potentiates the uptake of small extracellular vesicles by enhancing maturation of macropinosomes in hepatocellular carcinoma Cancer Commun. (IF 16.2) Pub Date : 2023-12-28 Yue Yao, Yi Xu, Liang Yu, Ting-Mao Xue, Zhi-Jie Xiao, Pui-Chi Tin, Hiu-Ling Fung, Hoi-Tang Ma, Jing-Ping Yun, Judy Wai Ping Yam
Small extracellular vesicles (sEVs) mediate intercellular communication that contributes to hepatocellular carcinoma (HCC) progression via multifaceted pathways. The success of cell entry determines the effect of sEV on recipient cells. Here, we aimed to delineate the mechanisms underlying the uptake of sEV in HCC.
-
Engineered extracellular vesicles: A new approach for targeted therapy of tumors and overcoming drug resistance Cancer Commun. (IF 16.2) Pub Date : 2023-12-28 Chen Ming-Kun, Chen Zi-Xian, Cai Mao-Ping, Chen Hong, Chen Zhuang-Fei, Zhao Shan-Chao
Targeted delivery of anti-tumor drugs and overcoming drug resistance in malignant tumor cells remain significant clinical challenges. However, there are only few effective methods to address these issues. Extracellular vesicles (EVs), actively secreted by cells, play a crucial role in intercellular information transmission and cargo transportation. Recent studies have demonstrated that engineered EVs
-
Association of previously irradiated stable brain metastases with outcomes of atezolizumab-treated non-small cell lung cancer: A pooled analysis of individual patient data from three randomized trials Cancer Commun. (IF 16.2) Pub Date : 2023-12-25 Tiantian Guo, Yue Zhou, Fei Liang, Zezhou Wang, Vincent Bourbonne, Lukas Käsmann, Nora Sundahl, Abraham Jing-Ching Wu, Jianjiao Ni, Zhengfei Zhu
Brain metastasis (BM) has long been recognized as a prognostic factor associated with poor prognosis for non-small cell lung cancer (NSCLC) in the era of conventional chemotherapy and targeted therapy [1]. In the era of immunotherapy, controversial findings have been reported regarding the prognostic significance of BM in patients with NSCLC treated with programmed death-1/programmed death-ligand 1
-
Multiomics analysis reveals metabolic subtypes and identifies diacylglycerol kinase α (DGKA) as a potential therapeutic target for intrahepatic cholangiocarcinoma Cancer Commun. (IF 16.2) Pub Date : 2023-12-24 Weiren Liu, Huqiang Wang, Qianfu Zhao, Chenyang Tao, Weifeng Qu, Yushan Hou, Run Huang, Zimei Sun, Guiqi Zhu, Xifei Jiang, Yuan Fang, Jun Gao, Xiaoling Wu, Zhixiang Yang, Rongyu Ping, Jiafeng Chen, Rui Yang, Tianhao Chu, Jian Zhou, Jia Fan, Zheng Tang, Dong Yang, Yinghong Shi
Intrahepatic cholangiocarcinoma (iCCA) is a highly heterogeneous and lethal hepatobiliary tumor with few therapeutic strategies. The metabolic reprogramming of tumor cells plays an essential role in the development of tumors, while the metabolic molecular classification of iCCA is largely unknown. Here, we performed an integrated multiomics analysis and metabolic classification to depict differences
-
Rescue of p53 functions by in vitro-transcribed mRNA impedes the growth of high-grade serous ovarian cancer Cancer Commun. (IF 16.2) Pub Date : 2023-12-22 Monika Raab, Izabela Kostova, Samuel Peña-Llopis, Daniela Fietz, Monika Kressin, Seyed Mohsen Aberoumandi, Evelyn Ullrich, Sven Becker, Mourad Sanhaji, Klaus Strebhardt
The cellular tumor protein p53 (TP53) is a tumor suppressor gene that is frequently mutated in human cancers. Among various cancer types, the very aggressive high-grade serous ovarian carcinoma (HGSOC) exhibits the highest prevalence of TP53 mutations, present in >96% of cases. Despite intensive efforts to reactivate p53, no clinical drug has been approved to rescue p53 function. In this study, our
-
Glucose-mediated mitochondrial reprogramming by cholesterol export at TM4SF5-enriched mitochondria-lysosome contact sites Cancer Commun. (IF 16.2) Pub Date : 2023-12-22 Ji Eon Kim, So-Young Park, Chulhwan Kwak, Yoonji Lee, Dae-Geun Song, Jae Woo Jung, Haesong Lee, Eun-Ae Shin, Yangie Pinanga, Kyung-hee Pyo, Eun Hae Lee, Wonsik Kim, Soyeon Kim, Chang-Duck Jun, Jeanho Yun, Sun Choi, Hyun-Woo Rhee, Kwang-Hyeon Liu, Jung Weon Lee
Transmembrane 4 L six family member 5 (TM4SF5) translocates subcellularly and functions metabolically, although it is unclear how intracellular TM4SF5 translocation is linked to metabolic contexts. It is thus of interests to understand how the traffic dynamics of TM4SF5 to subcellular endosomal membranes are correlated to regulatory roles of metabolisms.
-
Enhancing sensitivity of triple-negative breast cancer to DNA-damaging therapy through chemical inhibition of the m6A methyltransferase METTL3 Cancer Commun. (IF 16.2) Pub Date : 2023-12-15 Bianca Cesaro, Alessia Iaiza, Fabio Piscopo, Marco Tarullo, Eleonora Cesari, Dante Rotili, Antonello Mai, Alberto Diana, Michela Londero, Luca Del Giacco, Riccardo Masetti, Alba Di Leone, Chiara Naro, Silvia Masciarelli, Giulia Fontemaggi, Claudio Sette, Francesco Fazi, Alessandro Fatica
Dear Editor, N6-methyladenosine (m6A) is a critical mRNA modification catalyzed by the enzyme methyltransferase-like 3 (METTL3), with implications in RNA metabolism. METTL3 upregulation is associated with cancer progression, metastasis, and drug resistance, making it a potential therapeutic target [1]. The small-molecule METTL3 inhibitor, STM2457, has shown promise in treating acute myeloid leukemia
-
Cover Image, Volume 43, Issue 12 Cancer Commun. (IF 16.2) Pub Date : 2023-12-02 Yuting Li, Hanhao Zheng, Yuming Luo, Yan Lin, Mingjie An, Yao Kong, Yue Zhao, Yina Yin, Le Ai, Jian Huang, Changhao Chen
-
LncRNA-CCAT5-mediated crosstalk between Wnt/β-Catenin and STAT3 signaling suggests novel therapeutic approaches for metastatic gastric cancer with high Wnt activity Cancer Commun. (IF 16.2) Pub Date : 2023-11-27 Chenchen Liu, Aiwen Shen, Junquan Song, Lei Cheng, Meng Zhang, Yanong Wang, Xiaowen Liu
Although the constitutively activated Wnt/β-catenin signaling pathway plays vital roles in gastric cancer (GC) progression, few Wnt inhibitors are approved for clinical use. Additionally, the clinical significance of long non-coding RNAs (lncRNAs) in GC intraperitoneal dissemination (IPD) remains elusive. Here, we investigated the function and therapeutic potential of Wnt-transactivated lncRNA, colon
-
Multi-omic study to unmask genes involved in prostate cancer development in a multi-case family Cancer Commun. (IF 16.2) Pub Date : 2023-11-21 Lucia Chica-Redecillas, Sergio Cuenca-Lopez, Eduardo Andres-Leon, Laura Carmen Terron-Camero, Blanca Cano-Gutierrez, Jose Manuel Cozar, Jose Antonio Lorente, Fernando Vazquez-Alonso, Luis Javier Martinez-Gonzalez, Maria Jesus Alvarez-Cubero
Dear Editor, Hereditary prostate cancer (PC) comprises 5%-10% of all PC cases. The increased risk of PC in men with a family history of the disease is well known and is commonly caused by germline mutations, leading to clinical guidelines mentioning various genes for identifying high-risk individuals. However, the complex inheritance patterns involving multiple single nucleotide polymorphisms (SNPs)
-
Single-cell and bulk transcriptomics identifies a tumor-specific CD36+ cancer-associated fibroblast subpopulation in colorectal cancer Cancer Commun. (IF 16.2) Pub Date : 2023-11-21 Jin Wang, Ming-Jia Xi, Qing Lu, Bi-Han Xia, Yu-Zhi Liu, Jin-Lin Yang
Dear Editor, Cancer-associated fibroblasts (CAFs) are highly versatile and plastic cells in the tumor microenvironment. They have been identified as actively involved in cancer progression and metastasis through their various roles in remodeling the extracellular matrix, suppressing the immune response and reprogramming tumor metabolism [1]. However, many challenges exist in revealing the functional
-
Management of locally advanced non-small cell lung cancer: State of the art and future directions Cancer Commun. (IF 16.2) Pub Date : 2023-11-20 Da Miao, Jing Zhao, Ying Han, Jiaqi Zhou, Xiuzhen Li, Ting Zhang, Wen Li, Yang Xia
Lung cancer is the second most common and the deadliest type of cancer worldwide. Clinically, non-small cell lung cancer (NSCLC) is the most common pathological type of lung cancer; approximately one-third of affected patients have locally advanced NSCLC (LA-NSCLC, stage III NSCLC) at diagnosis. Because of its heterogeneity, LA-NSCLC often requires multidisciplinary assessment. Moreover, the prognosis
-
Cover Image, Volume 43, Issue 11 Cancer Commun. (IF 16.2) Pub Date : 2023-11-08 Ai Zhuang, Xiang Gu, Tongxin Ge, Shaoyun Wang, Shengfang Ge, Peiwei Chai, Renbing Jia, Xianqun Fan
-
Cover Image, Volume 43, Issue 11 Cancer Commun. (IF 16.2) Pub Date : 2023-11-08 Yongzhan Nie, Xianchun Gao, Xiqiang Cai, Zhen Wu, Qiaoyi Liang, Guobing Xu, Na Liu, Peng Gao, Jingyu Deng, Hongzhi Xu, Zhanlong Shen, Changqi Cao, Fenrong Chen, Nannan Zhang, Yongxi Song, Mingjun Sun, Chengyin Liu, Guangpeng Zhou, Weili Han, Jianhua Dou, Huahong Xie, Liping Yao, Zhiguo Liu, Gang Ji, Xin Wang, Qingchuan Zhao, Lei Shang, Daiming Fan, Xiaoliang Han, Jianlin Ren, Han Liang, Zhenning Wang
-
Mitochondria-targeted atovaquone promotes anti-lung cancer immunity by reshaping tumor microenvironment and enhancing energy metabolism of anti-tumor immune cells Cancer Commun. (IF 16.2) Pub Date : 2023-11-06 Donghai Xiong, Zheng Yin, Mofei Huang, Yian Wang, Micael Hardy, Balaraman Kalyanaraman, Stephen T Wong, Ming You
Atovaquone (ATO), a mitochondrial inhibitor, has anti-cancer effects [1]. Based on ATO, we developed mitochondria-targeted atovaquone (Mito-ATO) that had even stronger anti-tumor efficacy than ATO [2]. We synthesized Mito-ATO by attaching the bulky triphenylphosphonium (TPP) group to ATO via a ten-carbon alkyl chain (Supplementary file of methods; Supplementary Figure S1). To assess the effects of
-
Blockage of EGFR/AKT and mevalonate pathways synergize the antitumor effect of temozolomide by reprogramming energy metabolism in glioblastoma Cancer Commun. (IF 16.2) Pub Date : 2023-11-02 Xiaoteng Cui, Jixing Zhao, Guanzhang Li, Chao Yang, Shixue Yang, Qi Zhan, Junhu Zhou, Yunfei Wang, Menglin Xiao, Biao Hong, Kaikai Yi, Fei Tong, Yanli Tan, Hu Wang, Qixue Wang, Tao Jiang, Chuan Fang, Chunsheng Kang
Metabolism reprogramming plays a vital role in glioblastoma (GBM) progression and recurrence by producing enough energy for highly proliferating tumor cells. In addition, metabolic reprogramming is crucial for tumor growth and immune-escape mechanisms. Epidermal growth factor receptor (EGFR) amplification and EGFR-vIII mutation are often detected in GBM cells, contributing to the malignant behavior
-
Development and validation of an artificial intelligence model for predicting post-transplant hepatocellular cancer recurrence Cancer Commun. (IF 16.2) Pub Date : 2023-10-30 Quirino Lai, Carmine De Stefano, Jean Emond, Prashant Bhangui, Toru Ikegami, Benedikt Schaefer, Maria Hoppe-Lotichius, Anna Mrzljak, Takashi Ito, Marco Vivarelli, Giuseppe Tisone, Salvatore Agnes, Giuseppe Maria Ettorre, Massimo Rossi, Emmanuel Tsochatzis, Chung Mau Lo, Chao-Long Chen, Umberto Cillo, Matteo Ravaioli, Jan Paul Lerut
Dear Editor, In recent years, criteria based on the combination of morphology and biology have been proposed for improving the selection of hepatocellular cancer (HCC) patients waiting for liver transplantation (LT) [1, 2]. Since all the proposed models showed suboptimal results in predicting the risk of post-LT recurrence, a prediction model constructed using artificial intelligence (AI) could be
-
Targeted STAT1 therapy for LZTR1-driven peripheral nerve sheath tumor Cancer Commun. (IF 16.2) Pub Date : 2023-10-27 Tonci Ivanisevic, Mikhail Steklov, Benoit Lechat, Christopher Cawthorne, Willy Gsell, Greetje Vande Velde, Christophe Deroose, Koen Van Laere, Uwe Himmelreich, Raj N Sewduth, Anna A Sablina
Dear Editor, Schwannomas are peripheral nervous system tumors that cause chronic pain, numbness, and potentially life-threatening organ dysfunction. Surgery is a conventional treatment for schwannoma patients. However, those who undergo surgery may experience neurological deficits. Moreover, the management of schwannomas can be problematic due to their unpredictable growth. Thus, there is a pressing
-
Identification of telomere maintenance gene variations related to lung adenocarcinoma risk by genome-wide association and whole genome sequencing analyses Cancer Commun. (IF 16.2) Pub Date : 2023-10-26 Kouya Shiraishi, Atsushi Takahashi, Yukihide Momozawa, Yataro Daigo, Syuzo Kaneko, Takahisa Kawaguchi, Hideo Kunitoh, Shingo Matsumoto, Hidehito Horinouchi, Akiteru Goto, Takayuki Honda, Kimihiro Shimizu, Masahiro Torasawa, Daisuke Takayanagi, Motonobu Saito, Akira Saito, Yuichiro Ohe, Shun-ichi Watanabe, Koichi Goto, Masahiro Tsuboi, Katsuya Tsuchihara, Sadaaki Takata, Tomomi Aoi, Atsushi Takano,
Dear editor, Lung carcinoma is responsible for the highest fatality rate among cancer-related deaths globally, with lung adenocarcinoma (LADC) emerging as the prevailing subtype. LADC is characterized by two distinctive attributes in individuals of Asian ancestry: firstly, Asian patients with LADC are more frequently non-smokers (approximately 40%) than their European counterparts (around 10%) [1];
-
Dynamics and cytokinic regulation of immune cell infiltration in genetically engineered mouse models of pancreatic cancer dictate the sensitivity to immunotherapy Cancer Commun. (IF 16.2) Pub Date : 2023-10-25 Okan Safak, Shenghan Wang, Carmen Mota Reyes, Ibrahim Halil Gürcinar, Sergey Tokalov, Nedim Can Cevik, Kivanc Görgülü, Bengi Su Yilmaz, Emre Erdogan, Linhan Ye, Qiaolin Li, Elif Arik Sever, Samed Özer, Güldal Süyen, Helmut Friess, Güralp Onur Ceyhan, Rouzanna Istvanffy, Hana Algül, Ihsan Ekin Demir
Targeting the immune compartment in pancreatic ductal adenocarcinoma (PDAC) holds promise for prognostic improvement, yet our knowledge on the spatial and temporal dynamics and the molecular modulators of the PDAC-associated immunophenotype is scarce. Here, we quantified markers of several major immune cell subclasses longitudinally in the life span in the primary tumors of oncogenic Kras-driven murine
-
Beyond familial risk: deriving risk-adapted starting ages of screening among people with a family history of colorectal cancer Cancer Commun. (IF 16.2) Pub Date : 2023-10-24 Xuechen Chen, Thomas Heisser, Rafael Cardoso, Julia Hibbert, Michael Hoffmeister, Hermann Brenner
Dear Editor, Colorectal cancer (CRC) is the third most common cancer globally [1], even though a large proportion of those cancers would be preventable by screening. Among those with a family history (FH) of CRC, it is commonly recommended to start screening at younger ages, e.g., at age 40 or 10 years younger than the age at diagnosis of the youngest affected first-degree relative [2-5]. Even within
-
Spatial relationship of tertiary lymphoid structures and tumor-associated neutrophils in bladder cancer and prognostic potential for anti-PD-L1 immunotherapy Cancer Commun. (IF 16.2) Pub Date : 2023-10-20 Xuechun Wang, Anna Juncker-Jensen, Gang Huang, Mate Levente Nagy, Xuemin Lu, Liang Cheng, Xin Lu
Dear Editor, Tertiary lymphoid structures (TLSs) are organized clusters of immune cells found in non-lymphoid tissues of chronic inflammation, including solid tumors [1]. High endothelial venules (HEVs) positive for peripheral node addressin (PNAd) are present in TLSs and may provide highway entry for lymphocytes. Tumor-residing TLSs may be formed by the concerted actions of cytokines and chemokines
-
CD146 promotes malignant progression of breast phyllodes tumor through suppressing DCBLD2 degradation and activating the AKT pathway Cancer Commun. (IF 16.2) Pub Date : 2023-10-19 Jiewen Chen, Qingji Xu, Dan Liu, Xun Li, Mingyan Guo, Xuehui Chen, Jianyou Liao, Rong Lei, Wende Li, Hongyan Huang, Phei Er Saw, Erwei Song, Xiyun Yan, Yan Nie
As a rapid-progressing tumor, breast malignant phyllodes tumors (PTs) are challenged by the lack of effective therapeutic strategies and suitable prognostic markers. This study aimed to clarify the role and mechanism of CD146 on promoting PTs malignant progression, and to identify a novel prognosis marker and treatment target of breast malignant PTs.
-
Tumor microenvironment-dependent epigenetic imprinting in the vasculature predicts colon cancer outcome Cancer Commun. (IF 16.2) Pub Date : 2023-10-19 Elisabeth Naschberger, Maximilian Fuchs, Nicholas Dickel, Meik Kunz, Bernt Popp, Charles Gwellem Anchang, Richard Demmler, Yanmin Lyu, Steffen Uebe, Arif Bülent Ekici, Carol Immanuel Geppert, Arndt Hartmann, Christian Flierl, Katja Petter, Tobias Gass, Simon Völkl, Michael Scharl, Andreas Ramming, Claudia Günther, Susanne Merkel, Vera Simone Schellerer, Michael Stürzl
Dear Editor, Tumor microenvironment (TME)-dependent stromal cell plasticity governs tumor development and therapy response. Tumor endothelial cells (TECs) are a major cellular component in this context [1]. In colorectal carcinoma (CRC), the stromal cell-dependent impact of the TME is illustrated by an improved survival depending on an interferon (IFN)-γ-dominated Th1-like TME associated with high
-
Harnessing SARS-CoV-2-specific CD8+ T cells to kill target tumor cells for cancer immunotherapy Cancer Commun. (IF 16.2) Pub Date : 2023-10-19 Keunok Jung, Deok-Han Ko, Jeong-Yun Jang, Young Rong Kim, Jung Yeon Heo, Yong-Sung Kim
Dear Editor, During the coronavirus disease 2019 (COVID-19) pandemic era, many individuals were naturally infected with or vaccinated against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), resulting in the presence of cytotoxic CD8+ T cells (CTLs) specific to SARS-CoV-2 antigens, including the spike protein [1, 2]. Although these SARS-CoV-2-specific CTLs cannot eliminate cancer cells
-
Residual circulating tumor DNA after adjuvant chemotherapy effectively predicts recurrence of stage II-III gastric cancer Cancer Commun. (IF 16.2) Pub Date : 2023-10-14 Shu-Qiang Yuan, Run-Cong Nie, You-Sheng Huang, Ying-Bo Chen, Si-Yu Wang, Xiao-Wei Sun, Yuan-Fang Li, Ze-Kun Liu, Yan-Xing Chen, Yi-Chen Yao, Yu Xu, Hai-Bo Qiu, Yao Liang, Wei Wang, Ze-Xian Liu, Qi Zhao, Rui-Hua Xu, Zhi-Wei Zhou, Feng Wang
Circulating tumor DNA (ctDNA) is a promising biomarker for predicting relapse in multiple solid cancers. However, the predictive value of ctDNA for disease recurrence remains indefinite in locoregional gastric cancer (GC). Here, we aimed to evaluate the predictive value of ctDNA in this context.
-
Targeting mRNA translation aberrations: A novel approach for therapy in chronic lymphocytic leukemia Cancer Commun. (IF 16.2) Pub Date : 2023-10-06 Vanessa Klapp, Jerome Paggetti, Anne Largeot, Etienne Moussay
1 mRNA TRANSLATION IS AFFECTED IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AT VARIOUS LEVELS mRNA translation dynamics enable tight regulation of protein expression and rapid stress adaptation; however, its contribution to oncogenesis is overlooked compared to genetic and epigenetic aberrations. Aberrations in mRNA translation are a common feature of cancer and are established as a therapeutic vulnerability
-
Methionine restriction sensitizes cancer cells to immunotherapy Cancer Commun. (IF 16.2) Pub Date : 2023-10-06 Weiqin Lu, Yongde Luo
Altered metabolism is a defining characteristic of human cancer and holds significant diagnostic value in the clinic. A widely utilized diagnostic tool is the [18F] deoxyglucose-positron emission tomography (FDG-PET) scan, which is based on the fact that cancer cells prefer to uptake glucose, a phenomenon known as the Warburg effect. In addition to the notable shifts in glucose metabolism, cancer cells
-
Interactions of Indoleamine 2,3-dioxygenase-expressing LAMP3+ dendritic cells with CD4+ regulatory T cells and CD8+ exhausted T cells: synergistically remodeling of the immunosuppressive microenvironment in cervical cancer and therapeutic implications Cancer Commun. (IF 16.2) Pub Date : 2023-10-04 Xinyu Qu, Yumeng Wang, Qian Jiang, Tingting Ren, Chenyan Guo, Keqin Hua, Junjun Qiu
Cervical cancer (CC) is the fourth most common cancer in women worldwide. Although immunotherapy has been applied in clinical practice, its therapeutic efficacy remains far from satisfactory, necessitating further investigation of the mechanism of CC immune remodeling and exploration of novel treatment targets. This study aimed to investigate the mechanism of CC immune remodeling and explore potential
-
Physical activity and cancer risk: a dose-response analysis for the Global Burden of Disease Study 2019 Cancer Commun. (IF 16.2) Pub Date : 2023-09-24 Xiayao Diao, Yudong Ling, Yi Zeng, Yueqian Wu, Chao Guo, Yukai Jin, Xiaojiang Chen, Shoucheng Feng, Jianrong Guo, Chao Ding, Feiyu Diao, Zhicheng Du, Shanqing Li, Haibo Qiu
Adopting a healthy lifestyle, including regular physical activity, is widely believed to decrease cancer risk. This study aimed to quantitatively establish the dose-response relationships between total physical activity and the risk of breast, colon, lung, gastric, and liver cancers.
-
Cover Image, Volume 43, Issue 9 Cancer Commun. (IF 16.2) Pub Date : 2023-09-19 Yaoping Shi, Donghua Shi, Jiachang Chi, Dan Cui, Xiaoyin Tang, Yan Lin, Siying Wang, Zonghai Li, Haojie Jin, Bo Zhai
-
The crosstalk between ferroptosis and anti-tumor immunity in the tumor microenvironment: molecular mechanisms and therapeutic controversy Cancer Commun. (IF 16.2) Pub Date : 2023-09-17 Yichen Zheng, Lingqi Sun, Jiamin Guo, Ji Ma
The advent of immunotherapy has significantly reshaped the landscape of cancer treatment, greatly enhancing therapeutic outcomes for multiple types of cancer. However, only a small subset of individuals respond to it, underscoring the urgent need for new methods to improve its response rate. Ferroptosis, a recently discovered form of programmed cell death, has emerged as a promising approach for anti-tumor
-
Long-term antibiotic use and risk of hepatocellular carcinoma later in life: a nationwide cohort study of 9.8 million participants Cancer Commun. (IF 16.2) Pub Date : 2023-09-13 Seogsong Jeong, Sun Jae Park, Minseo Kim, Young Jun Park, Seulggie Choi, Jooyoung Chang, Ji Soo Kim, Yun Hwan Oh, Ahryoung Ko, Sang Min Park
Dear Editor, Antibiotics are considered indispensable in numerous treatments against infectious diseases. However, their over-prescription and widespread use are emerging as important global issues, as they lead to resistant bacteria, reducing the efficacy of antibiotics[1]. The defined daily doses per 1,000 habitants per day for antibiotics in South Korea is 28, which is much higher than the average
-
The SARS-CoV-2 spike protein induces lung cancer migration and invasion in a TLR2-dependent manner Cancer Commun. (IF 16.2) Pub Date : 2023-09-13 Mi-Jeong Kim, Ji Young Kim, Ji Hye Shin, Juhee Son, Yeeun Kang, Soo-Kyung Jeong, Duk-Hwan Kim, Kyun-Hwan Kim, Eunyoung Chun, Ki-Young Lee
Dear editor, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can lead to severe outcomes in patients with cancer [1]. It has been reported that patients with lung cancers disproportionately manifest severe COVID-19 with a high rate of hospitalization and death [2]. Notably, the SARS-CoV-2 Spike (S) protein can induce hyper-inflammation in both epithelial cells and macrophages
-
Transcriptomic analyses of localized prostate cancers of East Asian and North American men reveal race-specific luminal-basal and microenvironmental differences Cancer Commun. (IF 16.2) Pub Date : 2023-09-12 Melvin L. K. Chua, Alexander K. Hakansson, Enya H. W. Ong, Boon Hao Hong, Jing Jing Miao, Adelene Y. L. Sim, Janice S. H. Tan, Kah Min Tan, Gabrielle C. J. Lee, Kar Perng Low, Jeffrey K. L. Tuan, Terence W. K. Tan, Michael L. C. Wang, Joe P. S. Yeong, Michael C. S. Tan, Lui Shiong Lee, Ravindran Kanesvaran, Xin Zhao, Julian Ho, Daniel E. Spratt, Edward M. Schaeffer, Kae-Jack Tay, Yang Liu, Elai Davicioni
Dear editor, Prostate cancer (PCa) remains a major healthcare burden in men globally [1]. Most patients present with localized disease, and treatment is recommended based on risk classification systems like the National Comprehensive Cancer Network (NCCN) [2]. However, these methods are imprecise for estimating metastasis-free survival and prostate cancer-specific mortality and thus biomarkers that
-
Whitlockite has a characteristic distribution in mammary microcalcifications and it is not associated with breast cancer Cancer Commun. (IF 16.2) Pub Date : 2023-09-09 Carlo Morasso, Renzo Vanna, Francesca Piccotti, Lidia Frizzi, Marta Truffi, Sara Albasini, Camelia Borca, Thomas Huthwelker, Laura Villani, Oliver Bunk, Cinzia Giannini, Fabio Corsi
Dear Editor, Microcalcifications (MCs) are common findings in mammography and can be indicative of different degrees of malignancy, thus requiring multiple stereotaxis vacuum-assisted biopsies under mammography to identify and characterize breast cancer [1, 2]. In many cases, however, the presence of MCs is not associated with the presence of a tumor. Therefore, a better understanding of the physical-chemical
-
Transcription factor ETV4 promotes the development of hepatocellular carcinoma by driving hepatic TNF-α signaling Cancer Commun. (IF 16.2) Pub Date : 2023-09-05 Dandan Qi, Min Lu, Pengfei Xu, Xinli Yao, Yongchen Chen, Lipeng Gan, Yong Li, Yahua Cui, Xiaomei Tong, Shuhong Liu, Jingmin Zhao, Ningning Liu, Xin Ye
Hepatic inflammation is the major risk factor of hepatocellular carcinoma (HCC). However, the underlying mechanism by which hepatic inflammation progresses to HCC is poorly understood. This study was designed to investigate the role of ETS translocation variant 4 (ETV4) in linking hepatic inflammation to HCC.
-
JARID2 coordinates with the NuRD complex to facilitate breast tumorigenesis through response to adipocyte-derived leptin Cancer Commun. (IF 16.2) Pub Date : 2023-09-01 Wei Liu, Yi Zeng, Xinhui Hao, Xin Wang, Jiaxiang Liu, Tianyang Gao, Mengdi Wang, Jingyao Zhang, Miaomiao Huo, Ting Hu, Tianyu Ma, Die Zhang, Xu Teng, Hefen Yu, Min Zhang, Baowen Yuan, Wei Huang, Yunkai Yang, Yan Wang
Proteins containing the Jumonji C (JmjC) domain participated in tumorigenesis and cancer progression. However, the mechanisms underlying this effect are still poorly understood. Our objective was to investigate the role of Jumonji and the AT-rich interaction domain-containing 2 (JARID2) — a JmjC family protein — in breast cancer, as well as its latent association with obesity.
-
Intratumoral CD103+CD8+ T cells predict response to neoadjuvant chemoimmunotherapy in advanced head and neck squamous cell carcinoma Cancer Commun. (IF 16.2) Pub Date : 2023-09-01 Siqi Ren, Tianjun Lan, Fan Wu, Suling Chen, Xue Jiang, Chuying Huo, Zitian Li, Shule Xie, Donghui Wu, Ruixin Wang, Yanyan Li, Lin Qiu, Guoxin Huang, Shurui Li, Xiaojuan Wang, Meifeng Cen, Tingting Cai, Zhaoyu Lin, Jinsong Li, Bowen Li
Immune cell heterogenicity is known to determine the therapeutic response to cancer progression. Neoadjuvant chemoimmunotherapy (NACI) has shown clinical benefits in some patients with advanced head and neck squamous cell carcinoma (HNSCC), but the underlying mechanism behind this clinical response is unknown. The efficacy of NACI needs to be potentiated by identifying accurate biomarkers to predict
-
Combining methylated SEPTIN9 and RNF180 plasma markers for diagnosis and early detection of gastric cancer Cancer Commun. (IF 16.2) Pub Date : 2023-08-16 Yongzhan Nie, Xianchun Gao, Xiqiang Cai, Zhen Wu, Qiaoyi Liang, Guobing Xu, Na Liu, Peng Gao, Jingyu Deng, Hongzhi Xu, Zhanlong Shen, Changqi Cao, Fenrong Chen, Nannan Zhang, Yongxi Song, Mingjun Sun, Chengyin Liu, Guangpeng Zhou, Weili Han, Jianhua Dou, Huahong Xie, Liping Yao, Zhiguo Liu, Gang Ji, Xin Wang, Qingchuan Zhao, Lei Shang, Daiming Fan, Xiaoliang Han, Jianlin Ren, Han Liang, Zhenning Wang
Dear Editor, Early diagnosis is critical for successful treatment of gastric adenocarcinoma (GA). However, the sensitivities of tumor markers carcinoembryonic antigen (CEA), cancer antigen 19-9 (CA19-9) and CA72-4 for GA detection are approximately 20% [1], and the sensitivities of all markers combined for early gastric cancer detection is still very low [2]. DNA methylation plays a major role in tumorigenesis
-
Genomic information of children with malignant brain tumors for the prediction of length of hospitalization Cancer Commun. (IF 16.2) Pub Date : 2023-08-09 Yichuan Liu, Hui-Qi Qu, Xiao Chang, Frank D Mentch, Haijun Qiu, Kenny Nguyen, Xiang Wang, Amir Hossein Saeidian, Deborah Watson, Joseph Glessner, Hakon Hakonarson
Dear Editor: Central nervous system tumors in the brain or spine are the most common solid tumors in children, which accounts for about 25% of cancers in children younger than 15 years of age, and are the most common cause of cancer deaths in children [1]. The 5-year survival rate for central nervous system neoplasms has increased dramatically to 74% for patients under 18 years old (97% for benign/borderline
-
Cover Image, Volume 43, Issue 6 Cancer Commun. (IF 16.2) Pub Date : 2023-08-02 Zhimin Ma, Jun Lv, Meng Zhu, Canqing Yu, Hongxia Ma, Guangfu Jin, Yu Guo, Zheng Bian, Ling Yang, Yiping Chen, Zhengming Chen, Zhibin Hu, Liming Li, Hongbing Shen
-
MFSD2A potentiates gastric cancer response to anti-PD-1 immunotherapy by reprogramming the tumor microenvironment to activate T cell response Cancer Commun. (IF 16.2) Pub Date : 2023-08-04 Bin Zhang, Chun-Mei Wang, Hao-Xiang Wu, Feng Wang, Yang-Yang Chai, Ye Hu, Bing-Jing Wang, Zhou Yu, Rong-Hua Xia, Rui-Hua Xu, Xue-Tao Cao
The efficacy of anti-programmed cell death protein 1 (PD-1) immunotherapy in various cancers, including gastric cancer (GC), needs to be potentiated by more effective targeting to enhance therapeutic efficacy or identifying accurate biomarkers to predict clinical responses. Here, we attempted to identify molecules predicting or/and promoting anti-PD-1 therapeutic response in advanced GC (AGC).